阿托伐他汀钙联合新型依折麦布药物治疗冠心病的效果与临床安全性分析

目的分析冠心病患者应用阿托伐他汀钙联合新型依折麦布药物治疗的效果与临床安全性。方法96例冠心病患者,采用双盲法分为常规组和试验组,每组48例。常规组患者行阿托伐他汀钙治疗,试验组患者行阿托伐他汀钙联合新型依折麦布药物治疗。对比两组患者治疗效果、不良反应发生情况、血脂指标低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、血清甘油三酯(TG)、总胆固醇(TC)]水平。结果试验组治疗总有效率97.92%高于常规组的87.50%,差异有统计学意义(P<0.05)。治疗后,试验组患者的LDL-C(2.02±0.33)mmol/L、HDL-C(1.44±0.37)mmol/L、TG(1.81±0.17)mmol/L、TC(4.14±0.66)mmol/L优于常规组的(2.86±0.24)、(1.30±0.23)、(2.25±0.24)、(4.97±1.13)mmol/L,差异有统计学意义(P<0.05)。试验组不良反应发生率2.08%低于常规组的14.58%,差异有统计学意义(P<0.05)。结论对冠心病患者实施阿托伐他汀钙联合新型依折麦布药物治疗,能够优化患者血脂水平,改善患者临床症状,值得广泛应用。

Effect and clinical safety of atorvastatin calcium combined with new ezetimibe in the treatment of coronary heart disease

Objective To analyze the effect and clinical safety of atorvastatin calcium combined with new ezetimibe in the treatment of coronary heart disease.Methods A total of 96 patients with coronary heart disease were divided into conventional group and experimental group according to double-blind method,with 48 cases in each group.The conventional group was treated with atorvastatin calcium,and the experimental group was treated with atorvastatin calcium combined with new ezetimibe.The therapeutic effect,occurrence of adverse reactions,blood lipid indexeslow density lipoprotein cholesterol(LDL-C),high density lipoprotein cholesterol(HDL-C),serum triglyceride(TG),total cholesterol(TC)]were compared between the two groups.Results The total effective rate of treatment 97.92%of the experimental group was higher than 87.50%of conventional group,and the difference was statistically significant(P<0.05).After treatment,LDL-C(2.02±0.33)mmol/L,HDL-C(1.44±0.37)mmol/L,TG(1.81±0.17)mmol/L and TC(4.14±0.66)mmol/L of the experimental group were better than(2.86±0.24),(1.30±0.23),(2.25±0.24)and(4.97±1.13)mmol/L of the conventional group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions 2.08%of the experimental group was lower than 14.58%of conventional group,and the difference was statistically significant(P<0.05).Conclusion Atorvastatin calcium combined with new ezetimibe can optimize the blood lipid level and improve the clinical symptoms of the patient with coronary heart disease,which is worthy of wide application.